Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Velcade (bortezomib) for injection therapy for early relapsed prostate cancer.

Trial Profile

Velcade (bortezomib) for injection therapy for early relapsed prostate cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs Bortezomib (Primary) ; Bicalutamide; Flutamide; Goserelin; Leuprorelin
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Oct 2018 Status changed to discontinued due to low accrual
    • 31 Aug 2018 Biomarkers information updated
    • 27 Apr 2012 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top